Michael Schenker

11PUBLICATIONS
169CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyChemotherapyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Oct 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

|Feb 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler

|Dec 01, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.

Daniel S W Tan, Enriqueta Felip, Gilberto de Castro

Pageof 2

Frequent Collaborators

4 joint publications

Paolo A Ascierto

4 joint publications

Helen Gogas

4 joint publications

James Larkin

3 joint publications

Georgina V Long